SCHEMBL8937601

SCHEMBL8937601

CCCOc1ccc(C(=CC(=O)N2CCN(C(=O)c3cc(OC)c(OC)c(OC)c3)CC2)c2ccccc2)cc1OC

nearest known ligand 0.60

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.60
HSD17B10 Q99714 2/20 0.60
ALDH1A1 P00352 5/20 0.59
CYP1A2 P05177 1/20 0.59
SMN1; SMN2 Q16637 1/20 0.51
L3MBTL1 Q9Y468 2/20 0.50
KDM4E B2RXH2 1/20 0.49
CDK5 Q00535 1/20 0.48
CDK5R1 Q15078 1/20 0.48
TP53 P04637 1/20 0.48
POLB P06746 1/20 0.47
SLC29A1 Q99808 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8937598 1.00 HPGD (0.60) HPGDHSD17B10ALDH1A1CYP1A2SMN1; SMN2
SCHEMBL8937541 0.98 ALDH1A1 (0.59) HPGDHSD17B10ALDH1A1CYP1A2SMN1; SMN2
SCHEMBL8937537 0.98 ALDH1A1 (0.59) HPGDHSD17B10ALDH1A1CYP1A2SMN1; SMN2
SCHEMBL8937335 0.95 ALDH1A1 (0.58) HPGDHSD17B10ALDH1A1CYP1A2SMN1; SMN2
SCHEMBL8937329 0.95 ALDH1A1 (0.58) HPGDHSD17B10ALDH1A1CYP1A2SMN1; SMN2
SCHEMBL8937331 0.95 ALDH1A1 (0.58) HPGDHSD17B10ALDH1A1CYP1A2SMN1; SMN2
SCHEMBL8937415 0.92 ALDH1A1 (0.61) HPGDHSD17B10ALDH1A1CYP1A2SMN1; SMN2
SCHEMBL8937410 0.92 ALDH1A1 (0.61) HPGDHSD17B10ALDH1A1CYP1A2SMN1; SMN2
SCHEMBL8937413 0.92 ALDH1A1 (0.61) HPGDHSD17B10ALDH1A1CYP1A2SMN1; SMN2
SCHEMBL8937322 0.92 HPGD (0.57) HPGDHSD17B10ALDH1A1CYP1A2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0395446-B1 N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists SANKYO CO (JP) 1995-03-01 EP claimed
EP-0395446-A2 N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists Sankyo Company Limited (JP) 1990-10-31 EP claimed
US-5559109-A Method of treating a PAF-mediated pathology or for treating or preventing psoriasis, nephritis, asthma or shock by administering a PAF antagonist SANKKO COMPANY, LIMITED (JP) 1996-09-24 US disclosed
US-5556852-A PLATELET ACTIVATING FACTOR ANTAGONISTS SANKYO COMPANY, LIMITED (JP) 1996-09-17 US disclosed
EP-0395446-B1 N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists SANKYO CO (JP) 1995-03-01 EP disclosed
US-5369106-A N-acryloylpiperazine derivatives, their preparation and their use of PAF antagonists SANKYO COMPANY, LIMITED (JP) 1994-11-29 US disclosed
US-5192766-A Platelet activating factor antagonist SANKYO COMPANY, LIMITED (JP) 1993-03-09 US disclosed
EP-0395446-A2 N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists Sankyo Company Limited (JP) 1990-10-31 EP disclosed